ARTICLE | Clinical News
Enzon starts Prothecan Phase II
July 24, 2001 7:00 AM UTC
ENZN began open-label Phase II testing of its Prothecan pegylated camptothecin small molecule topoisomerase I inhibitor to treat small cell lung cancer. The 60-patient study will evaluate the anti-tum...